Introduction/Background Dostarlimab is a programmed death 1 (PD-1) inhibitor approved in the US as monotherapy in patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) advanced/recurrent EC that has progressed on or after platinum-based chemotherapy. We report efficacy endpoints by immune-related RECIST (irRECIST) per investigator assessment (IA) for the EC cohorts of the GARNET trial.

Methodology GARNET is a multicentre, open-label, single-arm phase 1 study. Assignment to cohort A1 (dMMR/MSI-H EC) or A2 (mismatch repair proficient [MMRp]/microsatellite stable [MSS] EC) was based on local assessment. Patients received 500 mg of dostarlimab intravenously Q3W for 4 cycles, then 1000 mg Q6W until disease progression, discontinuation, or withdrawal. Immune-related endpoints (irORR, irDOR, and irPFS) were prespecified secondary endpoints.

Results The irRECIST efficacy-evaluable population included 152 patients with dMMR/MSI-H EC and 160 patients with MMRp/MSI EC with measurable disease at baseline and who had 6 months' follow-up per IA. irORR and irDOR were similar to the primary endpoints of ORR and DOR by BICR per RECIST v1.1 (table 1). For dMMR/MSI-H, median irPFS was 11.2 months versus median PFS of 6.0 months, although the probability of remaining progression free at 6, 12, or 18 months was similar. Safety was previously reported.

Conclusion In line with the study primary endpoints, secondary efficacy endpoints by irRECIST demonstrate the benefit of dostarlimab in patients with EC.

2022-RA-1012-ESGO
THE ROLE OF INFLAMMATORY MARKERS IN THE PREOPERATIVE DIAGNOSIS OF ENDOMETRIAL CANCER AND ENDOMETRIAL HYPERPLASIA
1Cemal Resit Atalay, 2Funda Atalay. 1Gynecology and Obstetrics, ANKARA CITY HOSPITAL (Ankara Numune Education and Research Hospital), ANKARA, Turkey; 2Gynecologic Oncology, Surgery, Dr.AY Ankara Oncology Education and Research Hospital, ANKARA, Turkey

Introduction/Background Inflammation and immunogenesis are important for cancer progression and metastasis. Blood neutrophil lymphocyte ratio (NLR) and platelets lymphocytes ratio (PLR) are basic indicators of systemic inflammatory response. In addition high NLR is highlighted in patients with endometrial cancer. The aim of this study is to investigate the predictive role of NLR and PLR in cases of endometrial hyperplasia and cancer.

Methodology This retrospective study was performed between 2015–2020 with 469 cases, 78 nonatypical endometrial hyperplasia, 28 atypical endometrial hyperplasia, 79 endometrial adenocarcinoma and 284 controls who underwent an endometrial biopsy due to abnormal uterine bleeding and had a normal histopathology in two tertiary clinics. Blood samples were drawn from all patients before endometrial biopsy. Blood cell counts, NLRs and PLRs were compared among these groups.

Results The mean age of 469 patients was 49.01 ± 49.01. The mean age was 47.49 ± 6.85 in group 1, 50.93 ± 10.56 in group 2, 60.95 ± 8.81 in group 3 and 45.92 ± 6.80 in control group. The difference of age was significant between group 3, 2, 60.95 ± 8.81 in group 3 and 45.92 ± 6.80 in control group. The difference of age was significant between group 3 and 2, 60.95 ± 8.81 in group 3 and 45.92 ± 6.80 in control group. The difference of age was significant between group 3 and 2, 60.95 ± 8.81 in group 3 and 45.92 ± 6.80 in control group. The difference of age was significant between group 3 and 2, 60.95 ± 8.81 in group 3 and 45.92 ± 6.80 in control group. The difference of age was significant between group 3 and 2, 60.95 ± 8.81 in group 3 and 45.92 ± 6.80 in control group.
difference between the NLR measurements of the cases from different groups (p<0.001). Conclusion As a non-specific inflammatory marker, NLR was elevated in women with endometrial cancer. Simple, cheap and easy-to-perform, the NLR can be used as a potential inflammatory marker, for endometrial malignancy.

**2022-RA-1017-ESGO**  
**CONCURRENT ENDOMETRIAL CARCINOMA IN HYSTERECTOMY SPECIMENS IN PATIENTS WITH ATYPICAL ENDOMETRIAL HYPERPLASIA**

1 Cemal Resat Atalay, 2 Funda Atalay, 1 Gynecology and Obstetrics, ANKARA CITY HOSPITAL Ankara Numune Education and Research Hospital, ANKARA, Turkey; 2 Dr. AY Ankara Oncology Education and Research Hospital, ANKARA, Turkey

10.1136/ijgc-2022-ESGO.280

**Introduction/Background** The aim of this study was to evaluate the role of sub-histological types of atypical endometrial hyperplasia in the patient group treated with the diagnosis of atypical endometrial hyperplasia and whose final pathology is endometrial cancer.

**Methodology** A retrospective review of five years of patients (N = 94) who underwent hysterectomy for a diagnosis of atypical endometrial hyperplasia at a tertiary gynaecologic oncology center. Clinical and pathological characteristics were obtained.

**Results** The rate of concurrent endometrial carcinoma was 40.34% (n = 23) with most being stage 1A endometrioid histology. Significantly higher rates of carcinoma were reported in patients with complex atypical hyperplasia (86.95%) and EIN (13.04%). There was no patient who had simple atypia hyperplasia but whose pathology was endometrial cancer after hysterectomy.

**Conclusion** Complex atypical hyperplasia/EIN and postmenopausal status were significant predictors of concurrent endometrial carcinoma in patients with atypical endometrial hyperplasia.

**2022-RA-1019-ESGO**  
**ENDOMETRIAL HYPERPLASIA AND CANCER: RESULTS OF TWO REFERENCE HOSPITALS IN ANKARA**

1 Funda Atalay, 1 Cemal Resat Atalay, 1 Hacer Ozdemir. 1 Gynecologic Oncology Surgery, Dr. AY Ankara Oncology Education and Research Hospital, Ankara, Turkey; 2 Gynecology and Obstetrics, ANKARA CITY HOSPITAL (Ankara Numune Education and Research Hospital), ANKARA, Turkey

10.1136/ijgc-2022-ESGO.281

**Introduction/Background** Endometrial hyperplasia (EH) was classified by the World Health Organization in 2014 into two categories based on the presence of cytological atypia. Approximately, 200,000 new cases of EH are diagnosed annually in developed countries. EH is of significant clinical importance, given that it is the precursor of endometrial carcinoma, the most common gynecological cancer in developed countries.

**Methodology** We retrospectively reviewed the medical records of 675 cases with pathology results of nonatypical endometrial hyperplasia and above, out of 1122 patients who underwent endometrial biopsy for abnormal uterine bleeding at two referral hospitals in Ankara between 2015 and 2020. Data were extracted for age, menopausal status, endometrial thickness, presence of breast cancer, use of tamoxifen, symptoms, surgical treatment and histopathology.

**Results** Data of 675 patients were evaluated. The median age was 47 years (min 24-max 82). Transvaginal ultrasonography results of 530 patients were obtained, median endometrial thickness was 12 mm (min 3- max 40). 526 of the cases were premenopausal, 149 of them were postmenopausal. 12 of 23 cases with breast cancer were using tamoxifen. 32 of 675 cases were asymptomatic, 496 of them were abnormal uterine bleeding. 143 of them had endometrial biopsy with the diagnosis of postmenopausal bleeding. 164 of the cases were treated surgically.

**Conclusion** In the evaluation of 1122 patients who underwent endometrial biopsy due to abnormal uterine bleeding, endometrial hyperplasia and higher lesions were detected in 675 (60.16%) cases, and endometrial cancer was observed in 86 (7.66%) of these cases.

**2022-VA-1045-ESGO**  
**SENTINEL LYMPH NODE BIOPSY IN SURGICAL STAGING FOR ENDOMETRIAL CARCINOMA PATIENTS**

Laura Gil García, Ana Pérez-Cuéllar, Alejandro Muller Bravo, Marina Pérez Duce, Patryk Daniel Janiszewski, María De Cardenas Carrillo de Albornoz, Ana María Granado San Miguel, Jose Antonio Mestanza Garrido. Hospital General Universitario de Talavera de la Reina, Talavera de la Reina, Spain

10.1136/ijgc-2022-ESGO.282

**Introduction/Background** Sentinel lymph node mapping (SLN) has emerged as a reliable alternative for endometrial cancer (EC) lymph node assessment. Numerous studies have shown that SLN is comparable to LND in both low- and high-risk EC patients, and that oncological outcomes are similar between the SLN and LND groups (1, 2). The 2020 National Comprehensive Cancer Network guidelines (3) recommend surgical staging in low- and high-risk EC patients. The advantage of SLN lies in pathological superstaging, avoiding overtreatment and undertreatment.

We did retrospective single-center study, to evaluate the detection rate and diagnostic accuracy of the SLN procedure in predicting pathological iliac lymph node status in patients with early-stage endometrial cancer from 1 April 2020 to 1 February 2022.

**Methodology** SLN assessment using cervical injection with green indocyanine administered to the cervix (superficial 1 mm and deep 1-2 cm, 4 ml in total) and systematic dissection of pelvic lymph nodes in patients with FIGO stage I-II endometrial cancer. All lymph nodes were histopathologically examined, and SLNs were serially negative predictive value (NPV) of sentinel lymph node biopsy.

**Results** Overall, 22 patients, SLN group (21, 95%), and LND group (11, 50%) allowing us to correlate the results of both techniques. SLN were positive in 6 cases (28.5%) and LND were positive in 80% of cases. SLN mapping showed high sensitivity of 100% and negative predictive value of 100%, in our results.